688089 logo

Cabio Biotech (Wuhan) XSSC:688089 Stock Report

Last Price

CN¥15.65

Market Cap

CN¥2.6b

7D

-7.8%

1Y

-24.1%

Updated

28 May, 2024

Data

Company Financials +

Cabio Biotech (Wuhan) Co., Ltd.

XSSC:688089 Stock Report

Market Cap: CN¥2.6b

688089 Stock Overview

Develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers.

688089 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends2/6

Cabio Biotech (Wuhan) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cabio Biotech (Wuhan)
Historical stock prices
Current Share PriceCN¥15.65
52 Week HighCN¥23.50
52 Week LowCN¥9.98
Beta0.58
1 Month Change6.83%
3 Month Change22.07%
1 Year Change-24.13%
3 Year Changen/a
5 Year Changen/a
Change since IPO-55.52%

Recent News & Updates

Recent updates

Shareholder Returns

688089CN ChemicalsCN Market
7D-7.8%-3.2%-2.3%
1Y-24.1%-14.8%-10.6%

Return vs Industry: 688089 underperformed the CN Chemicals industry which returned -14.8% over the past year.

Return vs Market: 688089 underperformed the CN Market which returned -10.6% over the past year.

Price Volatility

Is 688089's price volatile compared to industry and market?
688089 volatility
688089 Average Weekly Movement9.2%
Chemicals Industry Average Movement7.2%
Market Average Movement7.1%
10% most volatile stocks in CN Market10.5%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 688089's share price has been volatile over the past 3 months.

Volatility Over Time: 688089's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
1999508Dewei Yiwww.cabio.cn

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

Cabio Biotech (Wuhan) Co., Ltd. Fundamentals Summary

How do Cabio Biotech (Wuhan)'s earnings and revenue compare to its market cap?
688089 fundamental statistics
Market capCN¥2.63b
Earnings (TTM)CN¥101.38m
Revenue (TTM)CN¥473.06m

26.0x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688089 income statement (TTM)
RevenueCN¥473.06m
Cost of RevenueCN¥283.08m
Gross ProfitCN¥189.98m
Other ExpensesCN¥88.60m
EarningsCN¥101.38m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.60
Gross Margin40.16%
Net Profit Margin21.43%
Debt/Equity Ratio0.7%

How did 688089 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

34%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.